TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06678659: A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

Sponsor: Recursion Pharmaceuticals Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 170 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT06678659 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06678659 Rescue Dossier →